Revenue Breakdown
Composition ()
No data
Revenue Streams
Cronos Group Inc (CRON) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cannabis Flower, accounting for 72.5% of total sales, equivalent to $26.36M. Other significant revenue streams include Cannabis Extracts and Other. Understanding this composition is critical for investors evaluating how CRON navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Cronos Group Inc maintains a gross margin of 35.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.22%, while the net margin is -1.10%. These profitability ratios, combined with a Return on Equity (ROE) of -0.88%, provide a clear picture of how effectively CRON converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CRON competes directly with industry leaders such as AVBP and BRBR. With a market capitalization of $1.01B, it holds a significant position in the sector. When comparing efficiency, CRON's gross margin of 35.45% stands against AVBP's N/A and BRBR's 29.13%. Such benchmarking helps identify whether Cronos Group Inc is trading at a premium or discount relative to its financial performance.
